| Market Cap | 211.68M |
| Revenue (ttm) | 58.86M |
| Net Income (ttm) | -16.98M |
| Shares Out | 22.00M |
| EPS (ttm) | -0.89 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 191,360 |
| Open | 9.83 |
| Previous Close | 9.90 |
| Day's Range | 9.45 - 9.94 |
| 52-Week Range | 2.38 - 10.34 |
| Beta | 1.62 |
| Analysts | Strong Buy |
| Price Target | 11.75 (+22.14%) |
| Earnings Date | Jul 29, 2025 |
About XGN
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and ot... [Read more]
Financial Performance
In 2024, Exagen's revenue was $55.64 million, an increase of 5.89% compared to the previous year's $52.55 million. Losses were -$15.12 million, -36.19% less than in 2023.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for XGN stock is "Strong Buy." The 12-month stock price target is $11.75, which is an increase of 22.14% from the latest price.
News
Exagen Inc. to Participate in Third Quarter Investor Conferences
CARLSBAD, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, today announced that management will participate in the following up...
Exagen Inc. (XGN) Q2 2025 Earnings Call Transcript
Exagen Inc. (NASDAQ:XGN) Q2 2025 Earnings Conference Call July 29, 2025 8:30 AM ET Company Participants Jeffrey G. Black - CFO & Corporate Secretary John Aballi - CEO, President & Director Ryan Dougl...
Exagen Inc. Reports Strong Q2 2025 Results
CARLSBAD, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2025,...
Exagen Inc. Appoints Chas McKhann to Board of Directors
CARLSBAD, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing solutions, announced today the appointment of Chas McKhann to its Boa...
Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025
CARLSBAD, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2025, ...
Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics
CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, is pleased to announce the appointment of Dr. Michael Mahler as Chie...
Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares
CARLSBAD, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has completed the sale of an additional 502,50...
Exagen Inc. Prices Public Offering of Common Stock
CARLSBAD, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of its previously announced underwritten p...
Exagen Inc. Announces Proposed Public Offering of Common Stock
CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has commenced an underwritten public offering ...
Exagen Inc. (XGN) Q1 2025 Earnings Call Transcript
Exagen Inc. (NASDAQ:XGN) Q1 2025 Earnings Conference Call May 5, 2025 8:30 AM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President & Chief Executive Officer Jeff Black - ...
Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume
CARLSBAD, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2025,...
Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors
$25 Million Funded at Close to Refinance Existing Debt and Extend Maturity Additional Borrowing Capacity Provides Minimally Dilutive Growth Capital CARLSBAD, Calif., April 28, 2025 (GLOBE NEWSWIRE) --...
Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To Profitability
We initiate coverage on Exagen with a Buy rating, citing a promising turnaround with growing diagnostics, improved margins, and new biomarker tests for lupus and RA. Despite a rocky history, Exagen's ...
Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025
CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2025, before th...
Exagen Inc. (XGN) Q4 2024 Earnings Call Transcript
Exagen Inc. (NASDAQ:XGN) Q4 2024 Results Conference Call March 11, 2025 8:30 AM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President & Chief Executive Officer Jeff Black ...
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights
Delivered record full-year total revenue and AVISE CTD average selling price Improved full-year adjusted EBITDA loss and cash use by over 40% Commercialized new biomarkers to enhance clinical utility ...
Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025
CARLSBAD, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter and year ended December 31, 2024...
Exagen Inc. to Participate in Upcoming Investor Conferences
CARLSBAD, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following upcoming inve...
Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results
New biomarkers on track for commercial launch in January 2025 Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted EBI...
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD
The milestone demonstrates AVISE CTD's value and adoption within the rheumatologic community, clearly demonstrating superior laboratory testing for improved patient care The milestone demonstrates AVI...
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
Significant enhancements will equip clinicians with even more diagnostic clarity in the treatment of patients with autoimmune disease Significant enhancements will equip clinicians with even more diag...
Exagen, Inc. (XGN) Q3 2024 Earnings Call Transcript
Exagen, Inc. (NASDAQ:XGN) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Ryan Douglas – IR John Aballi - President & CEO Jeffrey Black - CFO Conference Call Partic...
Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence
CARLSBAD, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of five abstracts at the 2024 American College o...
Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference
CARLSBAD, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the 2024 Cantor Global Healthca...
Exagen, Inc. (XGN) Q2 2024 Earnings Call Transcript
Exagen, Inc. (NASDAQ:XGN) Q2 2024 Earnings Conference Call August 5, 2024 8:30 AM ET Company Participants Ryan Douglas - IR John Aballi - President & CEO Conference Call Participants Kyle Mikson - Ca...